In an attempt to define possible subgroups ofAlzheimer's disease, 21 patients satisfying current clinical diagnostic criteria for this disorder were divided on the basis of progression rates of symptoms. Thirteen patients with relatively rapid intellectual deterioration did not differ from eight patients showing slow progression with respect to global intellectual performance, sex, or age at onset of symptoms. Neuropsychological testing revealed that although the two groups were indistinguishable in verbal or visuospatial functions associated with the parietotemporal cortex, the more rapidly deteriorating group had significantly greater impairment in executive functions attributed to the frontal lobe. PET scans showed equivalent reductions in glucose metabolism in the parietotemporal cortex, but patients with relatively fast progression had significantly greater hypometabolism frontally. These results suggest an association between relatively severe frontal lobe involvement and a rapid clinical course that might have important implications for the development of treatment strategies for patients with Alzheimer's disease.
Alzheimer's disease, characterised clinically by progressive cognitive deterioration, does not fit a uniform pattern.' 2 Indeed, the disorder has been subgrouped on the basis of age at onset,34 on morphological or neurochemical grounds,56 and on neuropsychological or cerebral imaging profiles.7 8 Distinct deficits in visuospatial or verbally mediated domains" as well as in specific memory functions10 have been applied to the categorisation of Alzheimer's patients. Positron emission tomography (PET) studies have shown that although regional glucose metabolism is characteristically reduced in the parietotemporal cortex., 12 portions of the frontal lobes may also be substantially affected in some patients. '3 14 The rate of symptom progression in Alzheimer's disease has long been known to vary widely, with illness ranging from only a few months' duration to as long as were found to have been further assessed by PETfluorodeoxyglucose scanning. None of these subjects had intercurrent medical illness or were receiving centrally active drugs at the time of testing. All had provided informed consent after full disclosure of the potential risks and benefits of this study.
An index of disease progression was calculated for each individual as:
140 -DRS score symptom duration where 140 was considered the lowest "normal" score on the dementia rating scale (DRS),'0 DRS score was the patient's current level of performance, and symptom duration was based on the patient's records and information provided by family members.'7 Subjects were then divided into a slowly progressive group, which included all those with an index below the midpoint of the entire range of values, and a rapidly progressive group, comprising those with an index higher than the midpoint.
General Positron emission tomography failed to show any group difference in regional cerebral metabolism in temporal, parietal, or occipital cortices, nor in any of the subcortical nuclei analysed (table 4) . In contrast, cortical metabolic values in the mesial and posterior regions of the superior frontal lobe bilaterally (Brodman area 6 to 9) were significantly lower in the rapidly progressive group (table 4) . Linear correlation analysis of the regional metabolic values with the progression indices revealed a significant decrease in metabolism with increasing rates of deterioration only in the superior frontal cortex (table 5) . No systematic differences were found between the left and right hemisphere. Regarding the degree of regional differences between groups, the most consistent metabolic differences again Table 2 Mean (SE) differences in cognitive functions between slowly and rapidly progressive groups of patients with Alzheimer's disease 
